Clinical Trial Detail

NCT ID NCT03821935
Title Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

urethra transitional cell carcinoma

oropharynx cancer

hepatocellular carcinoma

laryngeal squamous cell carcinoma

Advanced Solid Tumor

pancreatic adenocarcinoma

ureter transitional cell carcinoma

hypopharynx cancer

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

oral squamous cell carcinoma

triple-receptor negative breast cancer

Therapies

ABBV-151

ABBV-151 + ABBV-181

Age Groups: senior adult

No variant requirements are available.